# Study to Assess Safety and PET Imaging Characteristics of a Novel Senescence-specific Radiotracer [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside)

> **NCT04536454** · PHASE1,PHASE2 · UNKNOWN · sponsor: **University Hospital Tuebingen** · enrollment: 32 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** [18F]FPyGal

## Key facts

- **NCT ID:** NCT04536454
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-28
- **Primary completion:** 2023-06
- **Final completion:** 2024-06
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2021-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04536454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04536454, "Study to Assess Safety and PET Imaging Characteristics of a Novel Senescence-specific Radiotracer [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04536454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*